Cargando…

Novel drugs that target the metabolic reprogramming in renal cell cancer

Molecular profiling studies of tumor tissue from patients with clear cell renal cell cancer (ccRCC) have revealed extensive metabolic reprogramming in this disease. Associations were found between metabolic reprogramming, histopathologic Fuhrman grade, and overall survival of patients. Large-scale g...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Mijn, Johannes C., Panka, David J., Geissler, Andrew K., Verheul, Henk. M., Mier, James W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944519/ https://www.ncbi.nlm.nih.gov/pubmed/27418963 http://dx.doi.org/10.1186/s40170-016-0154-8

Ejemplares similares

Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b(+)/Gr-1(+) myeloid derived suppressor cells
por: Panka, David J, et al.
Publicado: (2013)

Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells
por: Panka, David J., et al.
Publicado: (2021)

Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
por: Liu, Qingjun, et al.
Publicado: (2011)

Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
por: Liu, Qingjun, et al.
Publicado: (2021)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
por: Labots, Mariette, et al.
Publicado: (2018)

Metabolic Reprogramming and Renal Fibrosis
por: Zhu, Xiaoyu, et al.
Publicado: (2021)

Novel genetically engineered mouse models for clear cell renal cell carcinoma
por: van der Mijn, Johannes C., et al.
Publicado: (2023)

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2022)

Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer
por: van der Mijn, Johannes C., et al.
Publicado: (2014)

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
por: Labots, Mariette, et al.
Publicado: (2020)

Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease
por: Wang, Mengdi, et al.
Publicado: (2022)

Metabolic reprogramming as a novel therapeutic target for Coxsackievirus B3
por: Kuk, Myeong Uk, et al.
Publicado: (2022)

MicroRNA-Mediated Metabolic Reprograming in Renal Cancer
por: Bogusławska, Joanna, et al.
Publicado: (2019)

Metabolic reprogramming of clear cell renal cell carcinoma
por: Zhu, Haiyan, et al.
Publicado: (2023)

Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma
por: Gu, Young-Ran, et al.
Publicado: (2022)

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
por: Zhang, Liang, et al.
Publicado: (2011)

Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection
por: Bachas, Costa, et al.
Publicado: (2018)

Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma
por: van der Mijn, Johannes C., et al.
Publicado: (2019)

Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2016)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015)

Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart
por: van der Pol, A., et al.
Publicado: (2020)

Targeting Lipid Metabolic Reprogramming as Anticancer Therapeutics
por: Cha, Ji-Young, et al.
Publicado: (2016)

Targeting Metabolic Reprogramming in Acute Myeloid Leukemia
por: Castro, Isabel, et al.
Publicado: (2019)

Targeting metabolic reprogramming in chronic lymphocytic leukemia
por: Nie, Yu, et al.
Publicado: (2022)

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
por: Pang, Yuyang, et al.
Publicado: (2023)

Targeting super-enhancers reprograms glioblastoma central carbon metabolism
por: Nguyen, Trang T.T., et al.
Publicado: (2021)

Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
por: Bao, Macus Hao-Ran, et al.
Publicado: (2021)

Metabolic reprogramming: A novel metabolic model for pulmonary hypertension
por: Liu, Xuhan, et al.
Publicado: (2022)

Attention Does Not Affect the Speed of Subjective Time, but Whether Temporal Information Guides Performance: A Large‐Scale Study of Intrinsically Motivated Timers in a Real‐Time Strategy Game
por: van der Mijn, Robbert, et al.
Publicado: (2021)

Lipid metabolism reprogramming and its potential targets in cancer
por: Cheng, Chunming, et al.
Publicado: (2018)

Translating Metabolic Reprogramming into New Targets for Kidney Cancer
por: Abu Aboud, Omran, et al.
Publicado: (2017)

Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last?
por: Van Wyngene, Lise, et al.
Publicado: (2018)

A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression
por: Agarwal, Ekta, et al.
Publicado: (2021)

Relationship between metabolic reprogramming and drug resistance in breast cancer
por: Lv, Linlin, et al.
Publicado: (2022)

Metabolic reprogramming in tumors: Contributions of the tumor microenvironment
por: Lane, Andrew N., et al.
Publicado: (2019)

A Metabolic Reprogramming of Glycolysis and Glutamine Metabolism Is a Requisite for Renal Fibrogenesis—Why and How?
por: Hewitson, Timothy D., et al.
Publicado: (2021)

Metabolic characterization of directly reprogrammed renal tubular epithelial cells (iRECs)
por: Lagies, Simon, et al.
Publicado: (2018)

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma
por: Lameirinhas, Ana, et al.
Publicado: (2019)

Involvement of FATP2-mediated tubular lipid metabolic reprogramming in renal fibrogenesis
por: Chen, Yuting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fckrtccuqslnik7t1bq15gh1ol